Article

POLITICO on 2024-01-31 18:16

Biogen to cease production of controversial Alzheimer's drug

The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer's disease treatment.

Related news

BBiogen Is Giving Away Its Controversial Alzheimer's Drug: Report 2 min read barrons.com
Florida
MBiogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decision marketwatch.com
Japan , Switzerland , Canada , Brazil , Australia
Biogen cutting cost of Alzheimer's drug Arkansas Online
Japan , Cambridge
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm WRAL
United States , Switzerland
WAlzheimer's drug from Biogen, partner receives FDA approval wraltechwire.com
Cambridge , Japan
Biogen shares soar as FDA reviewers support Alzheimer's drug Sydney Morning Herald
Wall Street , Massachusetts , Cambridge
Biogen And Eisai Present Positive Results For Experimental Alzheimer's Drug Forbes
Biogen trial drug shows promise in fight against Alzheimer's The Japan Times
Arizona , Phoenix , Switzerland , United States
Biogen says new drug shows promise in combating Alzheimer's metro.us
Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conference bizjournals.com
FDA calls for investigation of Biogen Alzheimer's drug approval bizjournals.com
Biogen reworks Alzheimer's drug pacts in bullish move bizjournals.com
Biogen stock gains on leaked Alzheimer's drug data bizjournals.com
San Diego
Biogen reanalyzes studies, presses ahead on Alzheimer's drug lasvegassun.com
Indianapolis , Wall Street , Mayo Clinic , United States , Japan
In reversal, Biogen to file for approval of Alzheimer's drug bizjournals.com
Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drug bizjournals.com